pimonidazole has been researched along with Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M; Benito, J; Borthakur, G; Bueso-Ramos, C; Cortes, J; Coveler, A; Daver, N; Estey, EH; Faderl, S; Feliu, J; Gu, Y; Gutheil, JC; Jabbour, E; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Kornblau, S; Lu, H; Melink, TJ; Nguyen, HQ; Pemmaraju, N; Ravandi, F; Thall, PF; Thomas, D; Wei, C; Wilson, WR; Yi, CA | 1 |
1 trial(s) available for pimonidazole and Neutropenia
| Article | Year |
|---|---|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers; Bone Marrow; Carbonic Anhydrase IX; Carbonic Anhydrases; Enterocolitis; Female; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Nitroimidazoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Recurrence; Remission Induction; Thrombocytopenia | 2015 |